The $30 Trillion Disease Nobody Talks About

Cardiovascular disease, cancer, diabetes and chronic respiratory illness kill 43 million people a year and cost the world economy tens of trillions of dollars, yet they still get a fraction of the attention and funding aimed at outbreaks and pandemics.

When people picture a global health emergency, they tend to picture something dramatic: a new virus, a hospital at capacity, a race for a vaccine. Non-communicable diseases (NCDs) rarely make that picture, even though they are, by a wide margin, the biggest killer on the planet. Cardiovascular disease, cancer, diabetes and chronic respiratory illness together account for 43.8 million deaths a year, three-quarters of all deaths worldwide that are not part of a pandemic. Heart disease and stroke alone kill roughly 19 million people annually, more than double the toll of cancer, the second largest contributor.

The chart below breaks down where that toll actually falls.

Cardiovascular disease dominates, but the "other NCDs" category, which includes kidney disease, dementia and a long list of chronic conditions, is larger than diabetes and nearly as large as chronic respiratory disease. This is not a story about one disease. It is a story about a whole category of illness that develops slowly, often silently, and eventually overwhelms both the people living with it and the health systems trying to treat it.

It is also worth being precise about what "non-communicable" means here, because the label can be misleading. These are not diseases people simply develop through bad luck or bad choices in isolation. Cardiovascular disease, cancer, chronic respiratory disease and diabetes share a set of underlying drivers, tobacco use, harmful alcohol consumption, physical inactivity, unhealthy diets and air pollution, that are shaped as much by environment, income and policy as by individual behaviour. Elevated blood pressure alone is linked to roughly one in five deaths globally. And a growing body of evidence shows that some NCDs are not even purely "non-communicable" in origin: infections such as hepatitis B, HPV and H. pylori are estimated to drive around 12% of cancers worldwide, disproportionately in lower-income regions, and hepatitis B-attributable chronic disease alone is projected to cost the world economy nearly $84 billion a year by 2035. The boundary between infectious and chronic disease, in other words, is far blurrier than the standard categories suggest.

A death toll concentrated in places least equipped to bear it

The regional distribution of this burden is where the economics get genuinely uncomfortable. Of all NCD deaths worldwide, 73% now occur in low- and middle-income countries, and 82% of premature NCD deaths, those before age 70, happen in the same places. These are health systems that are often simultaneously managing infectious disease control, maternal and child health, and a rapidly growing chronic disease burden, with a fraction of the resources available in high-income settings.

Kenya offers a useful illustration of what a serious response looks like in practice: the government has allocated the equivalent of billions of dollars to NCDs between 2021 and 2025, with over 40% earmarked specifically for cardiovascular disease and diabetes care and prevention. A recent PAHO analysis of South America similarly described NCDs and mental health conditions as a "major storm on the horizon" for the region's health and macroeconomic stability. These are not abstract warnings. They are health systems doing the arithmetic and concluding that the current trajectory is unaffordable.

Why this is a health economics story, not just a medical one

The reason NCDs deserve more attention than they get is not only the death toll. It is the economics. These are diseases that are expensive to treat, expensive to live with, and expensive to ignore.

In Europe alone, the World Health Organization estimates that NCDs cause 1.8 million avoidable deaths and cost the region roughly $514 billion every year, factoring in both healthcare spending and lost productivity. Widen the lens to the whole world and the numbers become almost hard to parse: one widely cited projection put the cumulative global economic cost of NCDs at around $30 trillion between 2010 and 2030. A more recent estimate, based on the Global Burden of Disease data, puts the cost of cancer alone at $25.2 trillion between 2020 and 2050.

What makes this particularly frustrating from a policy perspective is that a large share of this burden is preventable or treatable with existing tools. WHO's analysis suggests 60% of avoidable NCD deaths in Europe are linked to modifiable risk factors, tobacco, alcohol, poor diet, physical inactivity and high blood pressure, while the remaining 40% could be prevented or delayed through timely diagnosis and access to care. This is not a disease category where we are waiting for a scientific breakthrough. In most cases, we already know what works. The gap is between what we know and what health systems actually deliver.

The table below puts some of these figures side by side

Scope	Estimate	Timeframe	Source
WHO European Region	$514 billion/year, 1.8 million avoidable deaths/year	Annual	WHO/Europe, 2025
Global, cancer only	$25.2 trillion cumulative cost	2020-2050	GBD-based projection
Global, all major NCDs	$30 trillion cumulative cost	2010-2030	WEF/Harvard School of Public Health
Global investment case	$3/person/year additional investment → up to $1 trillion in economic benefit	By 2030	WHO, "Saving lives, spending less," 2025

That last row is arguably the most important one for policymakers. WHO's most recent investment case argues that a relatively modest increase in NCD spending, around $3 per person per year, could generate economic benefits of up to $1 trillion by 2030 through avoided treatment costs and preserved productivity. Between 2010 and 2019, 82% of countries did manage to reduce NCD mortality, but WHO notes that the pace of progress has slowed sharply since then, and some countries are now seeing NCD deaths rise again.

A funding mismatch that outlives every news cycle

It is worth putting these numbers next to how global health financing actually gets allocated. Emerging infectious disease threats, understandably, tend to dominate both media coverage and dedicated funding streams: pandemic preparedness, vaccine development, outbreak surveillance. These are legitimate and necessary investments. But NCDs, which kill roughly ten times more people each year than all infectious disease outbreaks combined, receive a strikingly small share of global health financing and international development assistance by comparison. Domestic health budgets in most countries remain skewed toward acute and hospital-based care, which is where NCDs typically get treated once they become severe, rather than toward the primary care and prevention infrastructure that would catch them earlier and far more cheaply.

This mismatch compounds over time in a fairly predictable way. A health system that under-invests in NCD prevention and early detection today is not simply deferring a cost, it is converting a manageable, treatable condition into an expensive, often irreversible one. Diabetes managed early through lifestyle support and basic medication is a fraction of the cost of diabetes managed late through dialysis and amputation. Hypertension caught in a routine GP appointment is a fraction of the cost of the stroke it eventually causes if it is not. The $30 trillion global cost estimate for NCDs between 2010 and 2030 is not, in other words, a fixed bill. A meaningful share of it reflects decisions, or the absence of decisions, about how early in the disease course health systems choose to intervene.

What this means beyond the numbers

There is a version of this story that is purely about money, and there is a version that is about who bears the cost. NCDs disproportionately affect low- and middle-income countries, where 82% of premature NCD deaths (before age 70) now occur, and where health systems are often least equipped to manage chronic, long-term conditions. Within wealthier countries, the burden also tracks socioeconomic deprivation: people in poorer areas are more likely to develop these conditions earlier, more likely to experience delays in diagnosis, and more likely to experience worse outcomes once they do. NCDs, in that sense, are not just an economic problem or a clinical problem. They are one of the clearest expressions of health inequality that exists, precisely because so much of the underlying risk is shaped by circumstances people did not choose: housing, income, access to affordable healthy food, and access to a GP who can catch a problem before it becomes a crisis.

None of this is an argument against continuing to invest in outbreak preparedness or pandemic response, both of which remain genuinely important. It is an argument for proportionality. A category of disease responsible for three-quarters of non-pandemic deaths worldwide, and tens of trillions of dollars in projected economic cost, arguably deserves a level of sustained political and financial attention closer to what pandemics receive in the aftermath of a crisis, rather than the comparatively quiet, chronic underfunding it has received for decades.

The public health case for investing in prevention and early treatment of NCDs has been made for over a decade. What has changed is the scale of the evidence now backing it, and the size of the bill accumulating in the meantime. As the WHO Regional Director for Europe put it bluntly: if NCDs were a virus, the world would be in lockdown. They are not a virus, so instead they quietly account for three out of every four deaths that are not part of a pandemic, and an economic burden that dwarfs almost anything else in global health.

Sources

• WHO Global Health Estimates 2021; WHO/Europe, "Avoidable mortality, risk factors and policies for tackling NCDs" (2025)

• WHO, "Saving lives, spending less" (2025)

• Global Burden of Disease Study 2021 (IHME)

• World Economic Forum/Harvard School of Public Health, "The Global Economic Burden of Non-Communicable Diseases